❌

Reading view

CD44v5 promotes triple-negative breast cancer cisplatin resistance by enhancing IL-4/IL-4Rα/STAT3 pathway and stabilizing membranous SLC7A11

Oncogenesis, Published online: 21 August 2026; doi:10.1038/s41389-026-00650-0

CD44v5 promotes triple-negative breast cancer cisplatin resistance by enhancing IL-4/IL-4Rα/STAT3 pathway and stabilizing membranous SLC7A11
  •  

Dual downregulation of HRK and BAD promotes BCL-xL-mediated docetaxel resistance in prostate cancer

Oncogenesis, Published online: 20 August 2026; doi:10.1038/s41389-026-00652-y

Dual downregulation of HRK and BAD promotes BCL-xL-mediated docetaxel resistance in prostate cancer
  •  

Disruption of the AR/ZNF217/PROM2 axis sensitizes prostate cancer to ferroptosis and enzalutamide therapy

Oncogenesis, Published online: 11 August 2026; doi:10.1038/s41389-026-00649-7

Disruption of the AR/ZNF217/PROM2 axis sensitizes prostate cancer to ferroptosis and enzalutamide therapy
  •  

SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8<sup>+</sup> memory T cell responses

Oncogenesis, Published online: 15 May 2026; doi:10.1038/s41389-026-00627-z

SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8+ memory T cell responses
  •  

Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU

Oncogenesis, Published online: 08 May 2026; doi:10.1038/s41389-026-00621-5

Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU
  •  

Metastasis suppressing properties of the cell-surface anchored serine protease prostasin: new functional and mechanistic insights from breast cancer

Oncogenesis, Published online: 17 April 2026; doi:10.1038/s41389-026-00615-3

Metastasis suppressing properties of the cell-surface anchored serine protease prostasin: new functional and mechanistic insights from breast cancer
  •  

Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma

Oncogenesis, Published online: 10 April 2026; doi:10.1038/s41389-026-00616-2

Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
  •  
❌